Ekso Bionics Holdings Beheer

Beheer criteriumcontroles 4/4

De CEO Ekso Bionics Holdings is Scott Davis, benoemd in Dec2022, heeft een ambtstermijn van 1.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 637.02K, bestaande uit 58.9% salaris en 41.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.47% van de aandelen van het bedrijf, ter waarde $ 71.77K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 3.4 jaar.

Belangrijke informatie

Scott Davis

Algemeen directeur

US$637.0k

Totale compensatie

Percentage CEO-salaris	58.9%
Dienstverband CEO	1.9yrs
Eigendom CEO	0.5%
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	3.4yrs

Recente managementupdates

Recent updates

Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 27% Cheaper

Nov 12

Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding

Aug 29

Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Jul 13

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

May 02

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Dec 20

Analyse CEO-vergoeding

Hoe is Scott Davis's beloning veranderd ten opzichte van Ekso Bionics Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$11m
Jun 30 2024	n/a	n/a	-US$12m
Mar 31 2024	n/a	n/a	-US$14m
Dec 31 2023	US$637k	US$375k	-US$15m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$15m
Dec 31 2022	US$1m	US$370k	-US$15m

Compensatie versus markt: De totale vergoeding ($USD 637.02K ) Scott } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).

Compensatie versus inkomsten: De vergoeding van Scott is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Scott Davis (54 yo)

1.9yrs

Tenure

US$637,020

Compensatie

Mr. Scott G. Davis serves as Chief Executive Officer of Ekso Bionics Holdings, Inc. since December 04, 2022 and serves as Director since December 08, 2022, and also served as its President & Chief Operatin...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Scott Davis	CEO & Director	1.9yrs	US$637.02k	0.47% $ 71.8k
Jerome Wong	Chief Financial Officer	2.4yrs	US$726.08k	0.20% $ 31.1k
Jason Jones	Chief Operating Officer	1.8yrs	US$710.24k	0.22% $ 33.5k
Rachael Anderson	Global Director of Marketing & Strategic Growth	3.8yrs	geen gegevens	geen gegevens
Ann Cookson	Human Resources Director	2.6yrs	geen gegevens	geen gegevens
Foon Chwee	President of APAC	6.8yrs	geen gegevens	geen gegevens
Stephan Aderhold	Senior VP & GM of EMEA	2.8yrs	geen gegevens	geen gegevens
Katherine Strausser	Principal Controls Engineer	no data	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

Ervaren management: Het managementteam van EKSO wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Scott Davis	CEO & Director	1.9yrs	US$637.02k	0.47% $ 71.8k
Sherri Medina	Member of Advisory Council	no data	geen gegevens	geen gegevens
Hans Keirstead	Member of Advisory Council	no data	geen gegevens	geen gegevens
Mary Cloyd	Independent Director	3.9yrs	US$147.01k	0.65% $ 98.2k
Corinna Lathan	Lead Independent Director	2.9yrs	US$158.13k	0.67% $ 102.2k
Nancy Byl	Member of Advisory Council	no data	geen gegevens	geen gegevens
Tom Kelley	Member of Advisory Council	no data	geen gegevens	geen gegevens
Daniel Kraft	Member of Advisory Council	no data	US$72.21k	geen gegevens
Kel Bergmann	Member of Advisory Council	no data	geen gegevens	geen gegevens
Graham Creasey	Member of Advisory Council	no data	geen gegevens	geen gegevens
Suzy Kim	Member of Advisory Council	no data	geen gegevens	geen gegevens
Charles Li	Independent Director	6.7yrs	US$143.10k	0.36% $ 54.6k

3.4yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EKSO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Ekso Bionics Holdings Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Executive Chairman of the Board recently sold US$66k worth of stock

High number of new and inexperienced directors

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Recent updates

Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 27% Cheaper

Consensus revenue estimates decrease by 11%, EPS upgraded

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ekso Bionics Holdings, Inc. to Report Q3, 2024 Results on Oct 28, 2024

New major risk - Shareholder dilution

Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $5.9971 million.

Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding

New major risk - Financial position

Forecast to breakeven in 2026

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Ekso Bionics Holdings, Inc. to Report Q2, 2024 Results on Jul 29, 2024

Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors

Consensus EPS estimates upgraded to US$0.43 loss, revenue downgraded

Price target increased by 8.1% to US$10.00

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Forecast to breakeven in 2026

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Ekso Bionics Holdings, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Consensus EPS estimates fall by 145%

Price target decreased by 7.5% to US$9.25

No longer forecast to breakeven

Full year 2023 earnings: EPS misses analyst expectations

Ekso Bionics Holdings, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Consensus estimates of losses per share improve by 26%

Forecast to breakeven in 2026

Ekso Bionics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR

Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal

New major risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ekso Bionics Holdings, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Ekso Bionics Holdings, Inc. Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 12%, EPS downgraded

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ekso Bionics Holdings, Inc. to Report Q2, 2023 Results on Jul 27, 2023

New minor risk - Share price stability

Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Executive Chairman of the Board recently sold US$66k worth of stock

Consensus EPS estimates fall by 40%

High number of new and inexperienced directors

No longer forecast to breakeven

Full year 2022 earnings released: US$1.16 loss per share (vs US$0.80 loss in FY 2021)

Forecast to breakeven in 2025

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million.

Price target decreased to US$9.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Ekso Bionics Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Ekso Bionics: Fragile Opportunity

Second quarter 2022 earnings: EPS exceeds analyst expectations

Ekso Bionics Holdings, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Is Ekso Bionics Holdings (NASDAQ:EKSO) A Risky Investment?

Ekso Bionics Holdings, Inc. Receives FDA Clearance to Market Its Eksonr(Tm) Robotic Exoskeleton for Use with Multiple Sclerosis Patients

Ekso Bionics Holdings, Inc. Announces Chief Financial Officer Changes

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 09, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Ekso Bionics Holdings, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Consensus forecasts updated